脂肪肝
脂质代谢
新陈代谢
胆汁酸
脂肪酸代谢
疾病
肝损伤
药物代谢
内科学
医学
生物
药理学
作者
Qinwei Yu,Zhenzhou Jiang,Luyong Zhang
标识
DOI:10.1016/j.pharmthera.2018.04.005
摘要
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence of significant alcohol consumption. Dysregulated bile acid (BA) metabolism is an important indicator in the pathology of NAFLD, which could progress into more severe forms of liver injury. Lipid metabolism, immune environment and intestinal bacteria are all affected by dysregulated BA metabolism directly, but the mechanisms remain unclear. Several drug candidates that target BA metabolism, either used alone or in combination with other agents, are currently under development for treatment of NAFLD. Here, we summarize the relationship of dysregulated BA metabolism and NAFLD, discuss the effects and mechanisms of dysregulated BAs-induced lipid metabolism disorder. Challenges in developing novel treatments are also discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI